XML 35 R24.htm IDEA: XBRL DOCUMENT
v3.26.1

Intangible Assets (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2026
Intangible Assets [Abstract] |
Schedule of Intangible Assets | Intangible assets consisted of the following:
Intangible Assets |  | March 31, 2026 |  |  | December 31, 2025 |
Licenses |  |  |  |  |  |  |  |
Non-Exclusive License Agreement |  | $ | 179,821 |  |  | $ | 179,821 |
Various generic drugs |  |  | - |  |  |  | 736,983 |
Four generic drugs (Encore) |  |  | - |  |  |  | 1,308,270 |
Needleless Syringe License |  |  | 26,060 |  |  |  | 26,060 |
Patents |  |  | 48,420 |  |  |  | 48,420 |
Mineral rights and exploratory |  |  | 48,416,474 |  |  |  | - |
Total intangible assets, net |  | $ | 48,670,775 |  |  | $ | 2,299,554 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of finite-lived intangible asset. Excludes goodwill. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 55 -Paragraph 40 -SubTopic 30 -Topic 350 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40 + Details
Name: | us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration